Navigation Links
PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013
Date:6/13/2013

in a Phase IIl clinical trial.  It also is developing long-acting versions of factor VIIa and factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development.  For more information, visit www.prolor-biotech.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, including statements regarding the results of current clinical studies and preclinical experiments and the effectiveness of PROLOR's long-acting protein programs, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ m
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.
2. Law Office of Brodsky & Smith, LLC Announces Investigation of PROLOR Biotech, Inc.
3. OPKO Health To Acquire PROLOR Biotech
4. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
5. PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
6. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
7. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
8. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
9. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
10. MedReps.com Report Shows Biotech Workers Earn the Most in Medical Sales
11. Biotechnology Master’s at UMBC Shady Grove - Virtual Info Session to Be Held on June 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 WriteResult, LLC – a ... been working with a team of researchers from Yale ... Community Farming Collaborative to provide electronic questionnaire data collection ... study, which started in May, aims to evaluate the ... weekly exposure to and participation in urban agriculture to ...
(Date:10/22/2014)... Rock Hill, SC (PRWEB) October 22, 2014 ... the expansion of its cardiovascular pharmacogenetics menu, which ... improved patient outcomes. With PCLS’s evidence-based results, ... individual needs and optimize their therapy, while minimizing ... , In the U.S., according to the FDA ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
Breaking Biology Technology:myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... York are pioneering the development of electron microscopes which ... materials in new revolutionary ways., The team, headed by ... University,s Department of Physics has created electron beams with ... will open the way to many novel applications including ...
... Inc. announced today the publication of key results relating ... discovery for high-value G-protein-coupled receptor (GPCR) targets in ... of a Lipid G Protein-Coupled Receptor," was co-authored by ... Ph.D., and Raymond Stevens, Ph.D. Drs. Rosen and Stevens ...
... Pa., Feb. 16, 2012  BioDelivery Sciences International, Inc. (Nasdaq: ... Trademark Office (USPTO) has issued a Notice of Allowance ... granted, will extend the exclusivity of the BioErodible MucoAdhesive ... Buprenorphine/Naloxone from 2020 to 2027.  A ...
Cached Biology Technology:York researchers create 'tornados' inside electron microscopes 2Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science 2Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science 3Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science 4BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals 2BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals 3BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals 4BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals 5
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
(Date:10/17/2014)... shown for the first time how bacteria can grow ... them the opportunity to get tremendous insights into bacteria ... also discovered the bacterial growth in chronic lung infections ... down by the immune cells. The researchers discovered the ... the bacteria, forcing the bacteria to switch to a ...
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2
... CORVALLIS, Ore. Fungi have significant potential for "horizontal" ... mechanisms that allow bacteria to evolve so quickly, become resistant ... to be published Thursday in the journal Nature , ... make-up of their genomes and become infectious to plants and ...
... like a mashup of monster movies, but palaeontologists have discovered ... a killing that took place 4 million years ago. ... by careful, forensic-style analysis of bite marks on an otherwise ... have reconstructed the events that led to the death of ...
... scientists have successfully used geometrically patterned surfaces to influence ... a departure from that of many stem-cell biologists, who ... controlling the fate of stem cells. "The cells ... it,s the shape alone that,s dictating whether they turn ...
Cached Biology News:Fungi can change quickly, pass along infectious ability 2Jaws -- 4 million B.C. 2